Synthego is a biotechnology company that provides CRISPR gene editing tools and services to researchers and pharmaceutical companies. The company specializes in manufacturing high-quality synthetic guide RNAs (gRNAs) and other CRISPR reagents, while also offering gene editing services and software platforms to support genetic research and therapeutic development.
Founded to democratize access to gene editing technology, Synthego has built automated manufacturing processes that enable scalable production of CRISPR components. The company serves academic institutions, biotech companies, and pharmaceutical firms working on gene therapies and genetic research. Synthego has raised significant venture funding and established itself as a key supplier in the rapidly growing gene editing market, contributing to advances in personalized medicine and genetic disease research.
Synthego has received investment from 1 venture capital firm.
Biotechnology company providing CRISPR gene editing tools, reagents, and services for research and therapeutic development.
Synthego has received investment from Delphi Ventures. These venture capital firms and investors provide both capital and strategic support.
Synthego operates in the Biotech sector. Biotechnology company providing CRISPR gene editing tools, reagents, and services for research and therapeutic development.
